The Congenital Heart Disease (CHD) Market Share Analysis provides the analysis of traders considering their contribution to the overall market. It gives the awareness of its revenue production into the complete market compared to other vendors in the universe. It delivers insights into exactly how dealers are execution in terms of revenue initiation and consumer base compared to others. Knowing market share presents an idea of the size and vendor competitiveness for the base year. It uncovers the market descriptions in terms of growth, breakup, supremacy, and incorporation attributes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Market Overview

The Congenital Heart Disease (CHD) market size was estimated at USD 4.47 billion in 2023 and is projected to reach USD 8.11 billion in 2030 at a CAGR of 8.87% during the forecast period 2023-2030.

Get a Sample Copy of the Report: https://www.delvens.com/get-free-sample/congenital-heart-disease-chd-market-trends-forecast-till-2030

Congenital Heart Disease (CHD) is a term used to describe a range of structural defects in the heart that are present at birth. These defects can involve the walls, valves, arteries, or veins of the heart, causing problems with blood flow and affecting the heart’s ability to pump blood effectively. Some congenital heart defects are mild and may not require treatment, while others can be more severe and require medical interventions such as surgery or medication. The exact cause of most congenital heart defects is not known, but a combination of genetic and environmental factors is thought to play a role.

The growth of the global Congenital Heart Disease (CHD) market is mainly driven by rising prevalence of congenital heart disease globally. Moreover, increased awareness, improved diagnostic techniques, increased awareness and better access to healthcare are expected to drive the market further. In addition, the growing emphasis on paediatric cardiology and specialized care for children are expected to drive the market further during the forecast period.

On the other hand, the high cost of treatment, limited healthcare infrastructure, and a complex regulatory environment might hamper the growth of the market during the forecast period.

The COVID-19 pandemic has had a significant impact on the growth if the Congenital Heart Disease (CHD) Market. The pandemic led to a decrease in the number of elective CHD surgeries, as hospitals prioritized the treatment of COVID-19 patients. Moreover, there was a delay in the diagnosis and treatment of CHD, as patients have been reluctant to seek medical care due to hear of contracting COVID-19. In addition, the pandemic led to an increase in the risk of complications for patients with CHD who do not contract COVID-19.

Key Findings

·         Based on type, the market is segmented into heart valve defects, heart wall defects, blood vessel defects, and others. The heart wall defects dominated the market in this segment. This is due to the increase in the cases of Ventricular septal defect (VSD) or hole in the heart worldwide.

·         Based on the diagnosis, the market is bifurcated into electrocardiogram, chest x-ray, echocardiogram, transoesophageal echocardiogram, pulse oximetry, exercise stress test, cardiac CT scan or MRI, cardiac catheterization, and others. Electrocardiograms dominated the market in this segment. This is because Electrocardiogram is the most common diagnostic tool to diagnose heart defects.

·         Based on treatment, the market is segmented into medications, surgery, watchful waiting, and others. Surgery dominated the market in this segment as it is the most common treatment for CHD. Surgical treatment can be performed in open-heart surgery or minimally invasive surgery.

·         Based on the route of administration, the market is segmented into oral, parenteral, and others. The oral route of administration dominated the market in this segment. Oral is the most common route of administration for medications. Medications taken by the mouth are absorbed into the bloodstream through the digestive system.

·         Based on end users, the market is segmented into hospitals, specialty clinics, others. Based on end users, the market is dominated by hospitals. This is because diagnosis and treatment of CHD are most prevalent in hospitals.

·         Based on distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and others. Hospital pharmacies dominated the market in this segment. This can be attributed to the fact that treatment for CHD is more prevalent in hospitals.

·         The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period due to the high prevalence of congenital heart disease and technological advancements in early diagnosis of the disease.

Regional Analysis

North America to Dominate the Market

·         North America is estimated to account for the largest market share during the forecast period. This is due to the high prevalence of congenital heart disease and technological advancements in early diagnosis of the disease.

·         Moreover, the strong presence of the key players in the region is expected to drive the market during the forecast period.

Competitive Landscape

·         Abbott Laboratories

·         AstraZeneca Plc

·         Becton Dickson & Co.

·         Bio-Rad Laboratories

·         Boston Scientific Corp.

·         Laboratory Corporation of America Holdings (LabCorp)

·         F. Hoffmann-La Roche Ltd.

·         Glaxosmithkline Plc

·         Janssen Pharmaceuticals, Inc.

·         Medtronic

·         Viatris Inc.

·         Novartis Ag

·         Pfizer, Inc.

·         Randox Laboratories Ltd.

·         Response Biomedical Corporation

·         Sanofi S.A.

·         Siemens Healthineers

·         Thermo Fisher Scientific Inc.

·         Vericel Corporation

To Grow Your Business Revenue, Make an Inquiry Before Buying at: https://www.delvens.com/Inquire-before-buying/congenital-heart-disease-chd-market-trends-forecast-till-2030

Recent Developments

·         In June 2023, Pfizer relaunched Eliquis, an anticoagulant used to prevent the gradual increase in the prevalence of stroke due to heart condition called atrial fibrillation which is a major concern being a common cause of death among adults.

·         In July 2023, Novartis announced that the US Food and Drug Administration (FDA) approved a label update for Leqvio (inclisiran) to enable earlier use in patients with elevated LDL-C who have an increased risk of heart disease, as an adjunct to diet and statin therapy.

Reasons to Acquire

·         Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.

·         Gain authentic and granular data access for the Congenital Heart Disease (CHD) Market to understand the trends and the factors involved in changing market situations.

·         Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.

·         In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Table of Contents

The Congenital Heart Disease (CHD) Market is segmented into various segments such as type, diagnosis, treatment, route of administration, end users, distribution channel, and region:

Based on Type

·         Heart Valve Defects

·         Heart Wall Defects

·         Blood Vessel Defects

·         Others

Based on Diagnosis

·         Electrocardiogram

·         Chest X-ray

·         Echocardiogram

·         Transoesophageal Echocardiogram

·         Pulse Oximetry

·         Exercise Stress Test

·         Cardiac CT Scan or MRI

·         Cardiac Catheterization

·         Others

Based on Treatment

·         Medications

·         Surgery

·         Watchful Waiting

·         Others

Based on Route of Administration

·         Oral

·         Parenteral

·         Others

Based on End Users

·         Hospitals

·         Specialty Clinics

·         Others

Based on Distribution Channel

·         Hospital Pharmacy

·         Retail Pharmacy

·         Others

Based on region

Asia Pacific

·         Japan

·         China

·         India

·         Australia

·         South Korea

·         Vietnam

·         New Zealand

·         Philippines

·         Thailand

·         Malaysia

·         Hong Kong

·         Taiwan

·         Singapore

·         Indonesia

·         Sri Lanka

·         Rest of Asia-Pacific

North America

·         U.S.

·         Canada

·         Mexico

Europe

·         Germany

·         U.K.

·         France

·         Italy

·         Spain

·         Sweden

·         Austria

·         Finland

·         Belgium

·         Turkey

·         Russia

·         Poland

·         Hungary

·         Czech Republic

·         Switzerland

·         Netherlands

·         Rest of Europe

South America

·         Brazil

·         Argentina

·         Chile

·         Colombia

·         Rest of South America

Middle East & Africa

·         South Africa

·         U.A.E.

·         Saudi Arabia

·         Oman

·         Qatar

·         Iran

·         Egypt

·         Rest of Middle East and Africa

Get Direct Order of this Report: https://www.delvens.com/checkout/congenital-heart-disease-chd-market-trends-forecast-till-2030

Browse Related Reports:

Vascular Imaging Market – Trends Forecast Till 2030

Blood Banking Devices Market – Trends Forecast Till 2030

Diagnostic Imaging Services Market – Trends Forecast Till 2030

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports, and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on the country, regional, and global business environment. We have a database for more than 45 industries globally in more than 115+ major countries.

Delvens database assists clients by providing in-depth information on crucial business decisions. Delvens offers significant facts and figures across various industries: Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, and Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

Contact Us:

UNIT NO. 2126, TOWER B,

21ST FLOOR ALPHATHUM

SECTOR 90 NOIDA 201305, IN

+44-20-8638-5055

SALES@DELVENS.COM